Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (30)

2024

  1. Cytomegalovirus UL44 protein induces a potent T-cell immune response in mice

    Antiviral Research, Vol. 227

  2. Natural history and prognostic factors of candidemia in kidney transplant recipients: A retrospective, multinational study

    Mycoses, Vol. 67, Núm. 1

2022

  1. Derivation of a score to predict infection due to multidrug-resistant Pseudomonas aeruginosa: a tool for guiding empirical antibiotic treatment

    Journal of Global Antimicrobial Resistance, Vol. 29, pp. 215-221

  2. Immunoguided Discontinuation of Prophylaxis for Cytomegalovirus Disease in Kidney Transplant Recipients Treated With Antithymocyte Globulin: A Randomized Clinical Trial

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 74, Núm. 5, pp. 757-765

  3. Progressive Multifocal Leukoencephalopathy

    Infectious Complications in Biologic and Targeted Therapies (Springer International Publishing), pp. 417-430

  4. Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events

    Atherosclerosis Plus, Vol. 48, pp. 37-46

2021

  1. COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?

    Transplantation, Vol. 105, Núm. 10, pp. 2146-2155

  2. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)

    Transplant infectious disease : an official journal of the Transplantation Society, Vol. 23, Núm. 3, pp. e13520

  3. IL-6–based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 5, pp. 1652-1661.e1

  4. Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study)

    Mycoses, Vol. 64, Núm. 11, pp. 1334-1345

  5. Invasive fusariosis in nonneutropenic patients, Spain, 2000-2015

    Emerging Infectious Diseases, Vol. 27, Núm. 1, pp. 26-35

  6. Pretransplant CMV-Specific T-Cell Immunity But Not Dose of Antithymocyte Globulin Is Associated With Recovery of Specific Immunity After Kidney Transplantation

    The Journal of infectious diseases, Vol. 223, Núm. 7, pp. 1205-1213

2020

  1. A critical review of the relationship between post-transplant atherosclerotic events and cytomegalovirus exposure in kidney transplant recipients

    Expert Review of Anti-Infective Therapy, Vol. 18, Núm. 2, pp. 113-125

  2. Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis

    Infectious Disease Clinics of North America, Vol. 34, Núm. 2, pp. 191-210

  3. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: A viewpoint in 2020

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 12, pp. 1532-1543

  4. Predictive tools to determine risk of infection in kidney transplant recipients

    Expert Review of Anti-Infective Therapy, Vol. 18, Núm. 5, pp. 423-441

  5. Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia

    American Journal of Transplantation, Vol. 20, Núm. 6, pp. 1629-1641

2019

  1. Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation

    American Journal of Transplantation, Vol. 19, Núm. 4, pp. 1139-1149

2018

  1. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)

    Clinical Microbiology and Infection, Vol. 24, pp. S71-S82

  2. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

    Clinical Microbiology and Infection, Vol. 24, pp. S41-S52